[HTML][HTML] Safety profile of molnupiravir in the treatment of COVID-19: A descriptive study based on FAERS data
G Santi Laurini, N Montanaro, D Motola - Journal of Clinical Medicine, 2022 - mdpi.com
Concerns have been raised about the actual benefit and safety of molnupiravir, a new
antiviral treatment for coronavirus disease 2019 (COVID-19). In order to provide additional …
antiviral treatment for coronavirus disease 2019 (COVID-19). In order to provide additional …
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
SH Khoo, R Fitzgerald, T Fletcher… - Journal of …, 2021 - academic.oup.com
Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …
What will be the role of molnupiravir in the treatment of COVID-19 infection?
A Vitiello, V Troiano, R La Porta - Drugs & Therapy Perspectives, 2021 - Springer
The global COVID-19 pandemic is currently underway. To date, there are approximately
4.55 million deaths and 219 million people infected [1]. The massive vaccination campaign …
4.55 million deaths and 219 million people infected [1]. The massive vaccination campaign …
Safety and efficacy of molnupiravir in SARS‐CoV‐2‐infected patients: A real‐life experience
A De Vito, A Colpani, A Bitti, B Zauli… - Journal of Medical …, 2022 - Wiley Online Library
Since the start of the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)
pandemic, several treatments have been proposed to cure coronavirus disease 2019 …
pandemic, several treatments have been proposed to cure coronavirus disease 2019 …
Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records
Objective To emulate a randomized target trial to estimate the association between the
antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 …
antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 …
[HTML][HTML] Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo …
MG Johnson, JM Strizki, ML Brown, H Wan… - Infection, 2023 - Springer
Purpose Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …
Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: a randomized, placebo-controlled trial
MG Johnson, A Puenpatom, PA Moncada… - Annals of internal …, 2022 - acpjournals.org
Background: In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction
in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk …
in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk …
Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic
Despite the progress in the management of COVID-19, effective oral antiviral agents are still
lacking. In the present review, the potential beneficial effects of molnupiravir in the …
lacking. In the present review, the potential beneficial effects of molnupiravir in the …
Analysis of all-cause hospitalization and death among nonhospitalized patients with type 2 diabetes and SARS-CoV-2 infection treated with molnupiravir or …
Importance Diabetes and COVID-19 are both global pandemics, and type 2 diabetes is a
common comorbidity in patients with acute COVID-19 and is proven to be a key determinant …
common comorbidity in patients with acute COVID-19 and is proven to be a key determinant …